We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Guangdong Fapon Biotech Co., Ltd.

Download Mobile App




Molecular AI Model Refines Risk Prediction in Pediatric Brain Tumors

By LabMedica International staff writers
Posted on 04 Nov 2026

Choosing treatment for a child with a malignant brain tumor requires balancing cancer control against lasting effects on learning, development, and quality of life. More...

This balance is complicated by differences in outcomes among children within the same clinical risk group. To help refine these assessments, researchers have developed an artificial intelligence model designed to provide more individualized survival predictions for pediatric brain tumors.

An international team led by Dana-Farber Cancer Institute (Boston, MA, USA) developed MANTIS, short for Methylation profiling and Artificial Neural networks for Time-dependent Individualized Survival predictions. The model uses DNA methylation profiling, a test already used in brain tumor diagnosis, to generate personalized survival predictions for children with medulloblastoma and ependymoma. Based on each tumor’s biology, it estimates how survival probability changes over time, providing information beyond broad risk classifications.

MANTIS combines genome-wide molecular data, including DNA methylation patterns and copy number changes, with long-term patient follow-up. Researchers initially developed the model for medulloblastoma, one of the most common malignant brain tumors in children, before extending the framework to ependymoma, another pediatric brain tumor with widely variable outcomes.

Across several large validation cohorts, MANTIS outperformed current risk-prediction approaches for many patients. The team also adapted it to estimate the likely effects of different radiation doses in medulloblastoma. Analysis suggested that more than half of children with average-risk medulloblastoma may be candidates for lower-dose craniospinal irradiation. In this group, lower-dose treatment was associated with better cognitive outcomes without a statistically significant survival disadvantage being detected.

Published in Nature Genetics on November 3, 2026, the findings build on molecular information already generated during routine tumor testing. The researchers suggested that similar AI-based methods could eventually extend to other pediatric and adult cancers in which patients sharing a diagnosis experience different clinical courses.

“Our goal is to move beyond broad risk categories and toward a more individualized understanding of each child's tumor. For children with brain tumors, that could help us better match treatment intensity to the biology of the disease and, ultimately, reduce long-term side effects for some patients,” said Volker Hovestadt, Ph.D., computational biologist at Dana-Farber and senior author of the study. 

“One exciting aspect of this work is that it shows how artificial intelligence can learn from molecular tests that are already part of care. With further clinical study, this type of approach could help support more personalized treatment decisions not only for pediatric brain tumors but potentially for many other cancers as well,” said Sabina Stefan, Ph.D., postdoctoral researcher at Dana-Farber and first author of the study.

Related Links
Dana-Farber Cancer Institute


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Gold Member
Platelet Function Analyzer
PL-12
Gold Member
NEW PRODUCT : SILICONE WASHING MACHINE TRAY COVER WITH VICOLAB SILICONE NET VICOLAB®
REGISTRED 682.9
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: The panel expands Cepheid’s respiratory testing portfolio on the GeneXpert platform, offering laboratories greater flexibility in selecting tests based on clinical needs. (Photo courtesy of Cepheid)

Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis

Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more

Microbiology

view channel
Image: Graphical Abstract (Matthew A Butzler, Jennifer L Reed, Alaina M Olson, et al. Development of a Rapid Automated Point-of-Care Test for Mycobacterium tuberculosis Detection from Tongue Swabs and Sputum Specimens on the DASH® Rapid PCR System, Open Forum Infectious Diseases, 2026; https://doi.org/10.1093/ofid/ofag706)

Rapid Point-of-Care Test Detects Tuberculosis from Tongue Swab and Sputum

Tuberculosis remains a major infectious disease challenge, particularly in regions with limited access to diagnostic testing and treatment. Diagnosis can be time-consuming, and collecting sputum samples... Read more

Pathology

view channel
Image Credit: Adobe Stock

New Training Approach Helps AI Distinguish Neighboring Cells in Tissue

Artificial intelligence (AI) can assist with identifying cells in digital pathology images, but densely packed tissue remains difficult to analyze. Neighboring cells may be merged, counted twice, or missed,... Read more

Industry

view channel
Image: The TOMR trial uses Signatera-guided MRD testing to identify high-risk patients for curative-intent treatment.

Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study

Natera (Austin, TX, USA) has entered into a clinical collaboration with Incyte (Wilmington, DE, USA) for a Phase II study evaluating molecular residual disease (MRD)-guided treatment in colorectal cancer.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.